<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05123716</url>
  </required_header>
  <id_info>
    <org_study_id>IRB21-0778</org_study_id>
    <nct_id>NCT05123716</nct_id>
  </id_info>
  <brief_title>Drug Effects on Interpersonal Interaction</brief_title>
  <acronym>DEI</acronym>
  <official_title>Drug Effects on Interpersonal Interaction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Chicago</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      We propose to use a Paired Partner design, in which subjects engage in a 45-min&#xD;
      semi-structured conversation with one (novel) partner under the influence of MDMA and with&#xD;
      another partner under the influence of placebo. At the end of each session, they will rate&#xD;
      their feelings about the partner, and on the test day, subjects will be asked which partner&#xD;
      they preferred and felt closer to.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will use a within-subject design with three sessions: i) MDMA and conversation with&#xD;
      Person A, ii) placebo and conversation with Person B, iii) test session (online) assessing&#xD;
      preference for Persons A and B. The MDMA dose will be 100 mg, administered under double blind&#xD;
      conditions. The conversation will consist of a 45 min dialog between the participant and the&#xD;
      partner, a person trained to engage in conversation for this purpose. The dyad will be&#xD;
      provided with topics to discuss, at their own pace. The order of administration of drug and&#xD;
      placebo will be counterbalanced, and the partners will be same-sex and varied across&#xD;
      sessions. The primary outcome measures will be feelings of closeness and connection at the&#xD;
      end of the two drug sessions, at the online test session and follow-up. After study&#xD;
      completion, participants will be fully informed about the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2021</start_date>
  <completion_date type="Anticipated">July 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2022</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Profile of Mood States</measure>
    <time_frame>Time Frame: Baseline-72 hours after completion of the sessions</time_frame>
    <description>The POMS measures individuals' mood states. This is a validated scale to measure positive and negative mood states. The POMS contains 30 items and assesses six identified mood factors: Tension-Anxiety, Depression-Ejection, Anger- Hostility, Vigor-Activity, Fatigue-Inertia, and Confusion-Bewilderment. Scoring of the instrument provides a global score of 0 to 120 or individual domain scores. Lower scores indicate better mood state. The POMS brief form is a simple self-rating instrument.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Interaction, Social</condition>
  <arm_group>
    <arm_group_label>Experimental: Placebo Then MDMA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants first receive placebo at their first session in the laboratory. Then will return to the laboratory 72 hours later and will receive 100 mg MDMA.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental: MDMA Then Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants first receive 100 mg MDMA at their first session in the laboratory. Then will return to the laboratory 72 hours later and will receive placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MDMA</intervention_name>
    <description>Participants will be given 100 mg of MDMA</description>
    <arm_group_label>Experimental: MDMA Then Placebo</arm_group_label>
    <arm_group_label>Experimental: Placebo Then MDMA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo oral tablet</intervention_name>
    <description>Participants will be given a placebo capsule that will only contain lactose.</description>
    <arm_group_label>Experimental: MDMA Then Placebo</arm_group_label>
    <arm_group_label>Experimental: Placebo Then MDMA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        English fluency High school level education BMI between 19 and 30&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Diagnosed medical condition women who are nursing, pregnant, or plan to become pregnant&#xD;
        within 3 months History of psychotic disorder or family history of psychotic disorder&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Matthew Bona</last_name>
    <phone>7737023560</phone>
    <email>dewitlab@yoda.bsd.uchicago.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew Bona</last_name>
      <phone>773-702-3560</phone>
      <email>dewitlab@yoda.bsd.uchicago.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 5, 2021</study_first_submitted>
  <study_first_submitted_qc>November 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 17, 2021</study_first_posted>
  <last_update_submitted>November 5, 2021</last_update_submitted>
  <last_update_submitted_qc>November 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

